‘Don't Doubt UNH Yet,' Top JPMorgan Analyst Defends UnitedHealth Stock amid Recent Volatility
Despite rising challenges, a Top-rated analyst, Lisa Gill from JPMorgan (JPM), remains confident about UnitedHealth Group (UNH). She recently reiterated a Buy rating on UNH stock with a $405 price target (33.4% upside potential). The bullish rating comes after a recent report by The Guardian about UNH's value-based contracts and hospitalization review processes.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Further, the company has faced major setbacks over the past week, including a CEO shakeup, a withdrawn financial outlook, and stock hitting a five-year low.
Importantly, UNH shares have dropped 20% since these developments.
Why JPMorgan Remains Bullish on UNH
The article raised concerns about how UnitedHealth evaluates Admissions Per 1,000 (APK), a metric used to manage care and reduce unnecessary hospital stays. However, Gill believes these practices are standard in the industry.
Also, Gill noted that hospitalization decisions are complex. While the article mentioned cases of nursing facilities struggling with hospitalization calls, the analyst does not see evidence of widespread misconduct.
Moreover, the five-star analyst highlighted that the U.S. Department of Justice (DOJ) had earlier probed these concerns but declined to charge the company.
At the same time, Gill remains confident in the company's fundamentals, viewing the recent sell-off as 'overdone' and the current valuation as an opportunity for investors.
Is UNH a Good Buy Right Now?
Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 19 Buys, six Holds, and one Sell assigned in the last three months. At $380.59, the average UnitedHealth stock price target implies a 25.62% upside potential.
See more UNH analyst ratings
Disclaimer & Disclosure Report an Issue
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Why GMS Stock Is Soaring Today
A bidding war appears to be brewing for building products distribution company GMS (NYSE: GMS), and investors are excited by the possibilities. Shares of GMS jumped 26% on Friday morning after the company was put in play by an unsolicited suitor. A building products bidding war? GMS is a construction products distributor and tool supplier for consumer and commercial customers. Late Wednesday, QXO (NYSE: QXO) proposed acquiring the business for about $5 billion, or $95.20 per share in cash, a premium of 27% to GMS's 60-day volume-weighted average. QXO is a roll-up put together by Brad Jacobs, the M&A specialist behind companies including XPO and United Rentals. The company did its first deal in April, acquiring Beacon Roofing Supply for $11 billion, and continues to seek out acquisition opportunities toward its goal to build a $50 billion business in the years to come. GMS said its board would review the proposal. QXO set a deadline of June 24 for a response, saying it intends to go directly to GMS shareholders if a deal can't be worked out. But QXO might have competition for the business. Late Thursday, The Wall Street Journal reported that Home Depot (NYSE: HD) has also made an offer for GMS. So far, Home Depot has not gone public with a bid, and it is unclear what price it is offering for GMS. Is GMS stock a buy? Though nothing is certain, with two deep-pocketed suitors, it appears likely that GMS's time as an independent company is nearing an end. And it is possible that, since there are two bidders, the sale will be for a higher price than the $95.20-per-share QXO offer. The market is already pricing that in, bidding GMS shares as high as $104 on Friday morning. Though both Home Depot and QXO have the resources to engage in a bidding war, both have smart management teams and solid strategies and seem unlikely to dramatically overpay. It is also unclear whether Home Depot was simply being opportunistic, or if the company considers GMS to be strategic enough to engage in a battle. Given the uncertainty of the outcome and the considerable premium already priced into GMS shares, investors should tread carefully. Should you invest $1,000 in Gms right now? Before you buy stock in Gms, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gms wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
an hour ago
- Globe and Mail
Val-d'Or Mining Closes Private Placement Financing
Val-d'Or, Québec--(Newsfile Corp. - June 20, 2025) - Further to its news release of May 9, 2025, Val-d'Or Mining Corporation (TSXV: VZZ) (the "Company") is pleased to announce that it has completed a non-brokered private placement offering (the "Offering") for gross proceeds of $704,600. The Company issued 14,092,000 Units under the Offering at a per Unit price of $0.05, each Unit comprised of one common share in the capital of the Company and one non-transferable common share purchase warrant (a "Warrant") exercisable for the purchase of one common share of the Company at a per share price of $0.075 until June 20, 2027. Six insiders participated in the Offering for aggregate cash consideration to the Company of $251,600, which constitutes a Related Party Transaction under TSX Venture Exchange Policy 5.9. The Company availed itself of the exemptions contained in section 5.5(c) of Multilateral Instrument 61-101 ("MI 61-101") for an exemption from the formal valuation requirement and Section 5.7(1)(b) of MI 61-101 for an exemption from the minority shareholder approval requirement of MI 61-101 as the fair market value of the securities to be distributed in the transaction, and the consideration to be received by the Company for those securities, insofar as the transaction involves interested parties did not exceed $2,500,000. In connection with the Offering, the Company paid cash finder's fees in the amount of $7,200 and issued 144,000 finder's warrants exercisable at a price of $0.075 until June 20, 2027, to arm's length finders. An administration fee of $6,000 was paid by the Company to one of the subscribers under the Offering. The net proceeds raised from the Offering will be used for the advancement of the Company's projects and for general corporate purposes. All securities issued under the Offering, including common shares underlying the Warrants and finder's warrants, are subject to a hold period until October 21, 2025, in accordance with applicable securities legislation and the policies of the TSX Venture Exchange. About Val-d'Or Mining Corporation Val-d'Or Mining Corporation is a junior natural resource issuer involved in the process of acquiring and exploring its mineral property assets, most of which are situated in the Abitibi Greenstone Belt of NE Ontario and NW Québec. To complement its current property interests, the Company regularly evaluates new opportunities for staking and/or acquisitions. Outside of its principal regional focus in the Abitibi Greenstone Belt, the Company holds several other properties in Northern Québec (Nunavik) covering different geological environments and commodities (Ni-Cu-PGE's). The Company has expertise in the identification and generation of new projects, and in early-stage exploration. The mineral commodities of interest are broad, and range from gold, copper-zinc-silver, nickel-copper-PGE to industrial and energy minerals. After the initial value creation in the 100%-owned, or majority-owned properties, the Company seeks option/joint venture partners with the technical expertise and financial capacity to conduct more advanced exploration projects. For additional information, please contact: Glenn J. Mullan 2772 chemin Sullivan Val-d'Or, Québec J9P 0B9 Tel.: 819-824-2808, x 204 Email: Forward-Looking Statements: This news release contains certain statements that may be deemed "forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or realities may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO SELL ANY OF THE SECURITIES DESCRIBED HEREIN IN THE UNITED STATES. THESE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.
Globe and Mail
an hour ago
- Globe and Mail
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) ('Lipella' or the 'Company'), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company's common stock from The Nasdaq Capital Market. Trading in the common stock was suspended at the open of business today. The delisting follows Nasdaq's determination that certain private placement transactions completed between December 2024 and March 2025 did not comply with Listing Rules 5100 (Public Interest Concern), 5635 (Shareholder Approval), and 5640 (Voting Rights). Specifically, Nasdaq cited the issuance of Series C voting convertible preferred stock and warrants to the Company's placement agent and advisor to those transactions, as having been structured in a way that triggered these rule violations. The Company was notified by the Hearings Panel of its determination to delist the Company's common stock effective today. Lipella is disappointed by this decision—particularly in light of the fact that it was taking immediate steps to obtain stockholder approval and address the concerns raised by Nasdaq. Lipella remains operationally sound, and its business fundamentals are intact. The Company is executing on its strategic and clinical development plans, including continued advancement of its lead product candidates LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus. In parallel, Lipella is actively exploring other markets to list its common stock and is committed to relisting its shares on a trading venue that provides the best possible liquidity and access for investors. The Company's common stock is currently quoted on the OTC Markets under the symbol 'LIPO.' 'We acknowledge Nasdaq's decision and are focused on taking swift, constructive steps accordingly,' said Dr. Jonathan Kaufman, Chief Executive Officer of Lipella. 'Our commitment to our shareholders, our mission, and our clinical goals has not changed.' The Company remains a reporting company under the Securities Exchange Act of 1934 and will continue to file periodic reports and disclosures with the U.S. Securities and Exchange Commission. Lipella will keep its stockholders informed of all material developments as it continues to assess its options. About Lipella Pharmaceuticals Inc. Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at and follow us on X and LinkedIn. Forward-Looking Statements This press release includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, including with respect to the Company's exploration of all markets and its commitment to list its common stock, future operations, financial position, prospects, clinical trials, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, general capital market risks, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein. CONTACT: Jonathan Kaufman Chief Executive Officer Lipella Pharmaceuticals Inc. Info@ 1-412-894-1853 PCG Advisory Jeff Ramson jramson@
